Stoke Therapeutics Leadership

Edward Kaye is a Board Member at CYTOKINETICS INC, Scientific Advisory Board at Lumos Pharma, and Board Member at STOKE THERAPEUTICS INC and is based in Boston, Massachusetts. He has worked as Board Member at SAREPTA THERAPEUTICS, INC.; Group VP:Clinical Development at Genzyme; and Associate Professor at University of PA School of Medcine. Edward works or has worked as MEMBER at CureDuchenne, MEMBER at Cure SMA, and MEMBER at United Leukodystrophy Foundation Inc. He attended Loyola University New Orleans, Loyola University Chicago between 1967 and 1971, and Loyola University Chicago Stritch School of Medicine.

Huw Nash is the Chief Operating Officer and Chief Business Officer of Stoke Therapeutics, and previously was the founding Chief Executive Officer. An Entrepreneur-in-Residence at Apple Tree Partners focused on novel therapeutics, Huw has 20 years of experience establishing, funding and growing start-up biotechnology companies. Prior to Stoke, Huw was a co-founder and Vice President of Corporate Development for Aileron Therapeutics (NASDAQ: ALRN). He was also a founding scientist of NeoGenesis Pharmaceuticals, where he served as Vice President of External Collaborations prior to the company’s acquisition by Schering-Plough. Huw received his B.A. in Biochemical Sciences from Harvard College and received his Ph.D. in Organic Chemistry from Harvard University.

Highly experienced and accomplished Finance and Accounting leader with a record of achievement managing the finances of companies in Pharma, BioPharma, and Technology.



Well versed in balance sheet, cash management, risk management, and Sarbanes Oxley compliance as well as treasury and tax matters including planning and compliance, contract negotiations, financial regulatory matters, long range plans, lease negotiations, human resource, payroll and benefits including salary negotiations and compensation planning.



A history of advancement through increasingly responsible leadership roles including Chief Financial Officer, and Secretary. Operationally practiced in the management of key business functions including Accounting, Finance, Information Technology, Pharma Supply Chain Management, Facilities Management, and Human Resource Management. Recognized as a hands-on manager with exceptional team building skills including cross-functional team leadership.

Specialties: Public Offerings • Joint Ventures • P&L’s • Project Management • Strategic Planning

Team Leadership & Motivation • Budgeting • Financial Analysis • Financial Statements • M&A • Reporting

Edward Kaye is a Board Member at CYTOKINETICS INC, Scientific Advisory Board at Lumos Pharma, and Board Member at STOKE THERAPEUTICS INC and is based in Boston, Massachusetts. He has worked as Board Member at SAREPTA THERAPEUTICS, INC.; Group VP:Clinical Development at Genzyme; and Associate Professor at University of PA School of Medcine. Edward works or has worked as MEMBER at CureDuchenne, MEMBER at Cure SMA, and MEMBER at United Leukodystrophy Foundation Inc. He attended Loyola University New Orleans, Loyola University Chicago between 1967 and 1971, and Loyola University Chicago Stritch School of Medicine.

Huw Nash is the Chief Operating Officer and Chief Business Officer of Stoke Therapeutics, and previously was the founding Chief Executive Officer. An Entrepreneur-in-Residence at Apple Tree Partners focused on novel therapeutics, Huw has 20 years of experience establishing, funding and growing start-up biotechnology companies. Prior to Stoke, Huw was a co-founder and Vice President of Corporate Development for Aileron Therapeutics (NASDAQ: ALRN). He was also a founding scientist of NeoGenesis Pharmaceuticals, where he served as Vice President of External Collaborations prior to the company’s acquisition by Schering-Plough. Huw received his B.A. in Biochemical Sciences from Harvard College and received his Ph.D. in Organic Chemistry from Harvard University.

Edward Kaye is a Board Member at CYTOKINETICS INC, Scientific Advisory Board at Lumos Pharma, and Board Member at STOKE THERAPEUTICS INC and is based in Boston, Massachusetts. He has worked as Board Member at SAREPTA THERAPEUTICS, INC.; Group VP:Clinical Development at Genzyme; and Associate Professor at University of PA School of Medcine. Edward works or has worked as MEMBER at CureDuchenne, MEMBER at Cure SMA, and MEMBER at United Leukodystrophy Foundation Inc. He attended Loyola University New Orleans, Loyola University Chicago between 1967 and 1971, and Loyola University Chicago Stritch School of Medicine.